Split-dose Versus Single-dose Polyethylene Glycol Regimen for Capsule Endoscopy

March 23, 2015 updated by: Pedro Magalhães-Costa, Centro Hospitalar Lisboa Ocidental

Split-dose Versus Single-dose Polyethylene Glycol Regimen for Capsule Endoscopy Is Timing of Preparation for Capsule Endoscopy the Key for the Best Small-bowel Cleansing?

To compare the small bowel cleanliness for wireless capsule endoscopy using two different Polyethylene Glycol administration schedules (before the wireless capsule endoscopy ingestion versus in a split-dose fashion).

Study Overview

Status

Unknown

Conditions

Detailed Description

The image quality obtained from the wireless capsule endoscopy improves its diagnostic yield. The amount of visualized mucosa is in direct correlation with the diagnostic yield. Nonetheless, frequently, the quality of the image obtained is hampered by the presence of bubbles, debris, bile and enteric fluid. Therefore many efforts have been putted in order to eliminate this factor such as the use of prokinetics, simethicone and bowel purgatives. The latter (namely the polyethylene glycol - PEG - solution) has accumulated evidence and is, therefore, recommended by the last European guidelines. Usually, the cleansing starts and finish in the day before the capsule endoscopy ingestion.

We hypothesized that, similarly to what had become evidence to large bowel cleansing, a shorter gap between the polyethylene glycol intake and the exam could provide a better capsule endoscopy image quality and therefore gauging our diagnostic yield.

Study Type

Interventional

Enrollment (Anticipated)

50

Phase

  • Phase 4

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

      • Lisboa, Portugal, 1349-019 Lisboa
        • Recruiting
        • Gastroenterology Department, Hospital Egas Moniz
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • All adult patients referred to our institution for CE during the study period

Exclusion Criteria:

  • inpatients, bedridden, patients with clinical evidence of active bleeding, past history of abdominal surgery, abdominal or pelvic radiation therapy, occlusion, bowel perforation (suspected or confirmed), use of oral iron replacement therapy, severe cardiopulmonary, renal or hepatic disease, pregnancy, hypersensitivity to any components of the preparation, patients that didn't complete the preparation protocol, patients with incomplete enteroscopies (a complete enteroscopy is defined by the visualization of the mucosa from the duodenal bulb to the cecum), patients enrolled in other clinical studies and patients who didn't signed informed consent.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Diagnostic
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Single-dose Polyethylene Glycol regimen
Drug: Polyethylene Glycol Intervention: 2 liters of Polyethylene Glycol will be given in the day before Capsule Endoscopy ingestion.
Endoscopic device
Bowel purgative
Other Names:
  • PEG
Experimental: Split-dose Polyethylene Glycol regimen
Drug: Polyethylene Glycol Intervention: 1 liter of Polyethylene Glycol will be given in the day before Capsule Endoscopy ingestion and another 1 liter Polyethylene Glycol will be given in the same day of Capsule Endoscopy ingestion.
Endoscopic device
Bowel purgative
Other Names:
  • PEG

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Small-bowel cleanliness
Time Frame: at the end of capsule endoscopy exploration
The cleansing quality of the small-bowel will be evaluated according to the system validated by Brotz et al., using the quantitative index (QI), because this score is less susceptible to the subjective element. The used cut-off value accepted for an adequate small-bowel cleansing was ≥ 8 points.
at the end of capsule endoscopy exploration

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
The number of all the observed lesions
Time Frame: at the end of capsule endoscopy exploration
Estimate the number of all the observed lesions on the recording according to their hemorrhagic potential.
at the end of capsule endoscopy exploration
The clinical tolerance questionnaire
Time Frame: at the end of capsule endoscopy exploration
Evaluate the clinical tolerance and the acceptability of the bowel preparation with the oral polyethylene glycol solution.
at the end of capsule endoscopy exploration
The transit time
Time Frame: at the end of capsule endoscopy exploration
Compare gastric transit time and the small bowel transit time.
at the end of capsule endoscopy exploration

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Director: Cristina Chagas, MD, Gastroenterology Department, Hospital Egas Moniz, Centro Hospitalar Lisboa Ocidental

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

March 1, 2015

Primary Completion (Anticipated)

May 1, 2015

Study Completion (Anticipated)

May 1, 2015

Study Registration Dates

First Submitted

February 18, 2015

First Submitted That Met QC Criteria

March 23, 2015

First Posted (Estimate)

March 24, 2015

Study Record Updates

Last Update Posted (Estimate)

March 24, 2015

Last Update Submitted That Met QC Criteria

March 23, 2015

Last Verified

March 1, 2015

More Information

Terms related to this study

Other Study ID Numbers

  • SPLIT-PEG-CE

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Bowel Preparation

Clinical Trials on Capsule endoscopy

3
Subscribe